科研之友
微信
新浪微博
Facebook
分享链接
摘要
The progression of prostate cancer to castration-resistant disease usually marks the transition of patient care from urologist to medical oncologist. The demonstration that a new generation of oral agents, such as abiraterone acetate, can be administered before chemotherapy suggests the dynamics of advanced prostate cancer care are about to change. Woo, H. H. Nat. Rev. Urol. 10, 133-134 (2013); published online 19 February 2013; doi:10.1038/nrurol.2013.25
- 出版日期2013-3
